SCHEMBL5159809

SCHEMBL5159809

CC(C)OC(=O)CC(=O)c1ccc2ccccc2n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.51
MAPT P10636 3/20 0.51
GAA P10253 2/20 0.51
KMT2A Q03164 2/20 0.51
HPGD P15428 2/20 0.50
SMN1; SMN2 Q16637 4/20 0.49
RAB9A P51151 3/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
MGAM O43451 1/20 0.49
KDM4E B2RXH2 2/20 0.47
KDM4C Q9H3R0 1/20 0.47
CNR2 P34972 2/20 0.45
MEN1 O00255 1/20 0.45
CYP1A2 P05177 2/20 0.44
NPC1 O15118 2/20 0.44
LMNA P02545 1/20 0.44
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160087 0.85 ALDH1A1 (0.58) ALDH1A1MAPTGAAKMT2AHPGD
SCHEMBL1460111 0.81 KMT2A (0.57) ALDH1A1MAPTGAAKMT2AHPGD
SCHEMBL9944376 0.80 KMT2A (0.69) ALDH1A1MAPTGAAKMT2AHPGD
SCHEMBL5070882 0.80 ALDH1A1 (0.51) ALDH1A1MAPTGAAKMT2AHPGD
SCHEMBL9664008 0.79 ALDH1A1 (0.60) ALDH1A1MAPTGAAKMT2AHPGD
SCHEMBL5162930 0.76 EGLN1 (0.44) MAPT
SCHEMBL5158144 0.76 ALDH1A1 (0.57) ALDH1A1MAPTGAAKMT2AHPGD
SCHEMBL5163053 0.75 ALDH1A1 (0.70) ALDH1A1MAPTGAAKMT2AHPGD
SCHEMBL8237398 0.75 MGAM (0.61) ALDH1A1MAPTGAAHPGDSMN1; SMN2
SCHEMBL30417045 0.75 MGAM (0.61) ALDH1A1MAPTGAAHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO ALDH1A1 273/4885MAPT 4661/4885GAA 1272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.